A once-daily liquid formulation of timolol maleate ophthalmic solution 0.5% (Istalol) has been approved for the topical treatment of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The new treatment is a product of Senju Pharmaceuticals.
According to Senju, Isalol is a nonselective beta-blocking agent that has enhanced corneal penetration, and the liquid formulation may help patients avoid vision blurring associated with gel formulations. The approval was based on the results of clinical trials that demonstrated comparable safety and efficacy between the once-daily and twice-daily timolol solutions.